logo image
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • SlatorCon Remote May 2021
    • Localizing at Scale for International Growth
    • Design Thinking May 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs
MENU
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • SlatorCon Remote May 2021
    • Localizing at Scale for International Growth
    • Design Thinking May 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs

Register Before April 15th for SlatorCon Remote and Save 15%!

  • Slator Market Intelligence
  • Slator Advertising Services
  • Slator Advisory
  • Login
Search
Generic filters
Exact matches only
Advertisement
Takeaways from Slator Executive Roundtable on China’s Drug Approval Reforms

5 years ago

July 20, 2016

Takeaways from Slator Executive Roundtable on China’s Drug Approval Reforms

Sponsored Content ·

by Slator

On July 20, 2016

5 years ago
Sponsored Content ·

by Slator

On July 20, 2016

Takeaways from Slator Executive Roundtable on China’s Drug Approval Reforms

China has embarked on the biggest regulatory overhaul of its pharmaceutical industry in more than 15 years. Among the drivers of change is Bi Jingquan, who was appointed Director of the China Food and Drug Administration (CFDA) in 2015.

The reform frenzy involving the launch of a full 22 new policies kicked off on April 24, 2015. China’s all-powerful Standing Committee approved a revision to the country’s Drug Administration Law, which forms the central piece of legislation governing the Chinese pharmaceutical industry. The revision removed preapproval requirements for drug companies and lifted state price controls on drugs.

On November 11, 2015, a CFDA circular was issued aiming to expand fast-track approval of new drugs and simplify clinical trials. On March 23, 2016, the CFDA published the first update to its medical device clinical trial guidance in 12 years, which asked companies to strengthen the informed consent process and increase the safety and efficacy of trials.

Advertisement

To discuss the reforms and their impact on the day-to-day operations of large pharmaceutical companies, medical device manufacturers, and clinical research organizations, Slator hosted an executive roundtable on July 12, 2016, in Shanghai.

Shangri-La Shanghai, the venue
Shangri-La Shanghai, the venue

The roundtable was sponsored by Lionbridge, one of the largest global providers of language services for the life sciences industry. Slator was pleased to welcome David Lv from Chinese law firm Global Law Office and a former official of the Shanghai Food and Drug Administration as expert speaker.

Participants included senior executives in operations and regulatory positions from leading pharma companies such as AstraZeneca, United Therapeutics, Boehringer-Ingelheim, Sanofi, Parexel, Novartis, Pfizer, Abbott, and China-based WuXi AppTec.

Speaker David Lv began by giving an overview of regulatory agencies at state, provincial, and local levels, which are involved in setting and executing policy in China. He continued by discussing the regulatory philosophy of previous and current CFDA directors that drives decision-making.

After providing a detailed glimpse into some of the core elements of recent regulatory reforms, Lv proceeded to share his unique insights as a former regulator on what companies can expect during onsite inspections. In fact, he shared that unannounced inspections are among the key new features of recently enacted reforms.

Some participants enjoying lunch
Some participants enjoying lunch

Lv concluded the discussion by providing a cautionary tale of a clinical trial gone wrong, where inadequate reporting and delayed action on adverse findings resulted in the revocation of the company’s license and even the filing of criminal charges against key employees.

Due to its sensitive nature, the roundtable was off-the-record and we are unable to go further into details of the lively discussion that took place between participants and the speaker. We can disclose, however, that participants pointed out document management and translation are key challenges in their daily operations, which will only intensify in days to come given the flurry of recent reforms.

Get in touch if you would like to know more about Slator Roundtables

TAGS

clinical researchclinical trial
SHARE
Slator

By Slator

Slator is the leading provider of news, analysis, and research for the global translation, localization, and language technology industry.

Advertisement

SUBSCRIBE TO THE SLATOR WEEKLY

Language Industry Intelligence
In Your Inbox. Every Friday

SUBSCRIBE

SlatorSweepSlatorPro
ResearchRFP CENTER

PUBLISH

PRESS RELEASEDIRECTORY LISTING
JOB ADEVENT LISTING

Bespoke advisory including speaking, briefings and M&A

SLATOR ADVISORY
Advertisement

Featured Reports

See all
Pro Guide: Translation Pricing and Procurement

Pro Guide: Translation Pricing and Procurement

by Slator

Slator 2020 Language Industry M&A and Funding Report

Slator 2020 Language Industry M&A and Funding Report

by Slator

Slator 2021 Data-for-AI Market Report

Slator 2021 Data-for-AI Market Report

by Slator

Slator 2020 Medtech Translation and Localization Report

Slator 2020 Medtech Translation and Localization Report

by Slator

Press Releases

See all
Smartling Announces Smartling+

Smartling Announces Smartling+

by Smartling

XTM Cloud 12.7 “Intelligent Connectivity” is Here

XTM Cloud 12.7 “Intelligent Connectivity” is Here

by XTM International

LocHub Announces QA Localization Solution For Multilingual Content Publishing Processes

LocHub Announces QA Localization Solution For Multilingual Content Publishing Processes

by Xillio

Upcoming Events

See All
  1. T-Update-2021

    T-UPDATE ’21 VIRTUAL

    by Gerard Castañeda

    · April 15

    Join us at the leading language Industry event for decision-makers. Just pack your agenda for 2 days and travel to the...

    More info €65-421

Featured Companies

See all
Sunyu Transphere

Sunyu Transphere

Text United

Text United

Memsource

Memsource

Wordbank

Wordbank

Protranslating

Protranslating

SeproTec

SeproTec

Versacom

Versacom

Smartling

Smartling

XTM International

XTM International

Translators without Borders

Translators without Borders

STAR Group

STAR Group

memoQ Translation Technologies

memoQ Translation Technologies

Advertisement

Popular articles

Google Translate Not Ready for Use in Medical Emergencies But Improving Fast — Study

Google Translate Not Ready for Use in Medical Emergencies But Improving Fast — Study

by Seyma Albarino

The Slator 2021 Language Service Provider Index

The Slator 2021 Language Service Provider Index

by Slator

DeepL Adds 13 European Languages as Traffic Continues to Surge

DeepL Adds 13 European Languages as Traffic Continues to Surge

by Marion Marking

SlatorPod: The Weekly Language Industry Podcast

connect with us

footer logo

Slator makes business sense of the language services and technology market.

Our Company

  • Support
  • About us
  • Terms & Conditions
  • Privacy Policy

Subscribe to the Slator Weekly

Language Industry Intelligence
In Your Inbox. Every Friday

© 2021 Slator. All rights reserved.

Sign up to the Slator Weekly

Join over 13,800 subscribers and get the latest language industry intelligence every Friday

Your information will never be shared with third parties. No Spam.